Nvidia: AI Leader Trading at an Attractive Valuation
July 1, 2025 Where to Rent Stable Turkish Datacenter Proxies?
June 24, 2025 PayPal’s News Analysis—A Short and Medium-Term Price Forecast
June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
Kiniksa Pharmaceuticals (KNSA) stock forecast for 2025
Updated: June 2, 2025 (09:12)
Sector: HealthcareThe share price of Kiniksa Pharmaceuticals, Ltd. (KNSA) now
50/200 Day Moving Average: $23.77 / $22.84
This figure corresponds to the Average Price over the previous 50/200 days. For Kiniksa Pharmaceuticals stocks, the 50-day moving average is the resistance level today.
For Kiniksa Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in Kiniksa Pharmaceuticals, Ltd. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Kiniksa Pharmaceuticals stock price in 2025. How much will one Kiniksa Pharmaceuticals share be worth in 2025? Is it worth taking profit / loss on KNSA stock now or waiting? What are analysts' forecasts for Kiniksa Pharmaceuticals stock?
We forecast Kiniksa Pharmaceuticals stock performance using neural networks based on historical data on KNSA stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Kiniksa Pharmaceuticals, Ltd. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Kiniksa Pharmaceuticals analysts is $38. Today 200 Day Moving Average is the support level (22.84 $). 50 Day Moving Average is the support level (23.77 $).
Historical and forecast chart of Kiniksa Pharmaceuticals, Ltd. stock
The chart below shows the historical price of Kiniksa Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the KNSA stock price can be found in the table below.
Kiniksa Pharmaceuticals, Ltd., a clinical stage biopharmaceutical company, specializes in the discovery, acquisition, development and commercialization of therapeutic drugs for severely ill patients with significant unmet medical needs around the world.
Kiniksa Pharmaceuticals (KNSA) Forecast for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jul | 28.82 | 26.01 | 30.32 | 14.21 % |
| Aug | 29.42 | 27.51 | 30.95 | 11.12 % |
| Sep | 27.81 | 25.57 | 30.60 | 16.43 % |
| Oct | 28.61 | 26.30 | 29.35 | 10.39 % |
| Nov | 27.60 | 26.81 | 29.04 | 7.66 % |
| Dec | 29.54 | 27.31 | 31.35 | 12.86 % |
Kiniksa Pharmaceuticals information and performance
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, BM
Market capitalization of the Kiniksa Pharmaceuticals, Ltd. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of KNSA shares in the company outstanding by the market price of one share.
EBITDA of Kiniksa Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Kiniksa Pharmaceuticals price target for 2025 by month
Target values for the price of one Kiniksa Pharmaceuticals share for Jul 2025.
In Jul, the Positive dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 14.211% volatility is expected.
Pessimistic target level: 26.01
Optimistic target level: 30.32
Target values for the price of one Kiniksa Pharmaceuticals share for Aug 2025.
In Aug, the Positive dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 11.121% volatility is expected.
Pessimistic target level: 27.51
Optimistic target level: 30.95
Target values for the price of one Kiniksa Pharmaceuticals share for Sep 2025.
In Sep, the Negative dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 16.426% volatility is expected.
Pessimistic target level: 25.57
Optimistic target level: 30.60
Target values for the price of one Kiniksa Pharmaceuticals share for Oct 2025.
In Oct, the Positive dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 10.390% volatility is expected.
Pessimistic target level: 26.30
Optimistic target level: 29.35
Target values for the price of one Kiniksa Pharmaceuticals share for Nov 2025.
In Nov, the Negative dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 7.662% volatility is expected.
Pessimistic target level: 26.81
Optimistic target level: 29.04
Target values for the price of one Kiniksa Pharmaceuticals share for Dec 2025.
In Dec, the Positive dynamics for Kiniksa Pharmaceuticals, Ltd. shares will prevail with possible monthly volatility of 12.864% volatility is expected.
Pessimistic target level: 27.31
Optimistic target level: 31.35
